Health Care · Pharmaceutical Preparations

MNKD MANNKIND CORP SEC Filings & Insider Trading Activity 2026

company
CIK 899460116 filings
Russell 2000

MNKD at a glance

MANNKIND CORP (MNKD, SEC CIK 899460) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MANNKIND CORP (MNKD) reported revenue of $349.0 million (up 22.2% from FY2024) and net income of $5.9 million. Diluted EPS was $0.02.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding MANNKIND CORP (MNKD) shares worth $334.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Binder Steven B. on September 25, 2026 of 39,051 shares at $3.29 per share.
  • In the last 90 days, MNKD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($256K) on Form 4, a net sale of $256K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$349.0M
+22.2% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$256K
13F holders
28 funds
$334.8M · −2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: biopharmaceutical company focused on inhalation drug delivery and proprietary pulmonary technologies
  • New emphasis: multiple amendments (up to seventh) to Commercial Supply Agreement with United Therapeutics Corporation in current year
  • Strategic shift: continuation and expansion of collaboration and supply agreements rather than new product launches or segments
  • Notable metric: numerous contract amendments in fiscal 2026, including the Seventh Amendment to Commercial Supply Agreement dated January 7, 2026
  • Unusual fact: substantial focus in filing on detailed biographies of board members highlighting extensive pharma leadership experience

Risk Factors

  • Regulatory risk: Inflation Reduction Act of 2022 limited insulin copays to $35/month for Medicare Part D starting 2023, pressuring Afrezza pricing and reimbursement
  • Geopolitical risk: V-Go wholly manufactured in China, exposed to U.S.-China trade tensions and potential tariff changes affecting margins
  • Operational risk: Single-source supplier of insulin for Afrezza from Amphastar, creating vulnerability to supply disruptions
  • Competitive risk: United Therapeutics’ Tresmi with up to 90% less coughing may displace Tyvaso DPI, materially impacting royalty revenue
  • Financial risk: scPharma acquisition funded by debt increased interest expense, leverage, and debt service requirements significantly

Management Discussion & Analysis

  • Cardiometabolic segment consists of Afrezza, Furoscix, V-Go device with recent acquisition of scPharma in Oct 2025
  • No forward-looking outlook, guidance, or emerging risks mentioned in the provided text

AI summary of the MNKD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New competitive risk: United Therapeutics’ February 2026 Tresmi plans could divert emphasis from Tyvaso DPI and materially reduce MannKind royalties
  • New international trade risk: recently announced tariffs could raise costs for up to 36 months before contract repricing
  • Regulatory risk: OBBBA reduced insurance coverage and Medicaid enrollment, potentially lowering demand and reimbursement for commercial products
  • Operational risk: Yutrepia launched in June 2025, creating direct competition with Tyvaso DPI for treprostinil market share
  • Financial risk: Blackstone Credit Facility requires at least $40.0 million quarterly liquidity and restricts additional debt, acquisitions, and asset sales

Management Discussion & Analysis

  • Revenue $101.9M, up $19.7M YoY from $82.1M
  • Commercial product sales $45.0M, up $22.7M YoY, led by Furoscix net revenue $22.4M
  • Commercial product gross margin decreased 5% YoY, primarily from lower-margin Furoscix on-body infusor
  • Operating cash use $58.3M through nine months, versus $26.2M generated YoY
  • Capital resources $96.6M; $49.8M private-placement proceeds funded $44.8M CVR payment
  • Near-term liquidity covered at least 12 months; tariff-related sourcing costs and Furoscix ReadyFlow adoption remained headwinds

AI summary of the MNKD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • November 5, 2026 press release announces MannKind’s fiscal-year 2026 results
  • Full financial results and management commentary are in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $101.9M, up 24%, led by Furoscix $22.4M and commercial product revenue $45.0M, up 102%
  • Furoscix ReadyFlow reached approximately 75% of weekly shipments, signaling rapid post-approval adoption and potential Q4 revenue acceleration
Filed Aug 21, 2026Full analysis →

Item 8.01: Other Events

  • Prospectus supplement filed August 21, 2026 under automatic shelf registration No. 333-285286
  • Legal opinion supports potential issuance and sale of MannKind common stock
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • August 5, 2026 press release covers MannKind’s fiscal-year 2026 results
  • Key financial figures and management commentary are contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $109.4M, up 43%, led by $22.2M Furoscix sales and $35.0M collaborations and services
  • Afrezza sales fell 7% to $17.0M, while pediatric approval and early prescribing by 1 in 3 top-100 pediatric insulin writers support recovery potential

AI summaries of MNKD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MNKD

Don't miss the next MNKD filing

  • Alerts as it files. A push when MNKD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MNKD, by share count.
  • Ask anything. An AI agent that reads every MNKD filing and answers with sources.

MNKD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Friedman Michael AMNov 17, 2026-
Friedman Michael AMNov 17, 2026$1.10
Friedman Michael AFNov 17, 2026$4.07
Binder Steven B.SellSep 25, 2026$3.29
Binder Steven B.SellSep 10, 2026$3.81
Binder Steven B.SellAug 7, 2026$4.06
Thomson DavidSellJul 17, 2026$4.05
Binder Steven B.SellJul 17, 2026$4.06

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$285.5M$349.0M
Operating Income-$72.6M$38.8M
Net Income-$11.9M$27.6M$5.9M
Op. Margin-25.4%11.1%
Net Margin-9.7%1.7%
Balance Sheet
Total Assets-$393.8M$792.2M
Equity-$246.2M-$78.8M-$51.0M
ROE4.8%-35.0%-11.5%
Per Share
EPS$-0.04$0.10$0.02
Cash Flow
Operating CF-$42.5M$18.3M
CapEx$42.4M$9.7M$4.6M

Source: XBRL data in MANNKIND CORP (MNKD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MNKD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MNKD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$334.8M
Q2 202630$395.4M
Q1 202630$255.7M
Q4 202527$537.4M
Q3 202529$495.6M
Q2 202531$354.7M
Q1 202528$329.6M
Q4 202424$343.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 227 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MNKD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Sep 28, 2026--
4Sep 14, 2026--
8-KAug 21, 2026Analysis-
SC 13GAug 14, 2026-
4Aug 10, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
SC 13GJul 31, 2026-
8-KJul 24, 2026Analysis-
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
8-KJun 2, 2026Analysis
8-KMay 28, 2026Analysis
4May 22, 2026-
8-KMay 22, 2026Analysis
4May 22, 2026-
4May 22, 2026-

Related Health Care companies

All Health Care →

MNKD SEC filings: frequently asked questions

Are MNKD insiders buying or selling?

In the last 90 days, MANNKIND CORP (MNKD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $256,334 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MNKD stock?

As of September 30, 2026, the largest MANNKIND CORP (MNKD) holders among the 13F filers tracked by SignalX were BlackRock ($128.4 million), State Street Corp ($58.9 million), Vanguard Capital Management LLC ($55.3 million), Goldman Sachs Group ($12.3 million), Vanguard Portfolio Management LLC ($12.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MNKD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MANNKIND CORP (MNKD) reported revenue of $349.0 million (up 22.2% from FY2024) and net income of $5.9 million. Diluted EPS was $0.02. The figures come from the XBRL data in the 10-K.

What are the main risks in MNKD's latest 10-K?

In the 10-K filed February 26, 2026, MANNKIND CORP (MNKD) flagged: Regulatory risk: Inflation Reduction Act of 2022 limited insulin copays to $35/month for Medicare Part D starting 2023, pressuring Afrezza pricing and reimbursement. Geopolitical risk: V-Go wholly manufactured in China, exposed to U.S.-China trade tensions and potential tariff changes affecting margins. (AI summary of the Risk Factors section.)

What did MNKD report in its latest 8-K?

MANNKIND CORP (MNKD) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). November 5, 2026 press release announces MannKind’s fiscal-year 2026 results.

What are the latest MNKD SEC filings?

MANNKIND CORP (MNKD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.

What is MNKD's SEC CIK number?

MANNKIND CORP (MNKD)'s SEC Central Index Key (CIK) is 899460. EDGAR lists every MNKD filing under that number.

Ask anything about MNKD

The research agent reads MNKD's filings, financials, insider trades and 13F holders, then answers with sources.